论文部分内容阅读
目的探讨英夫利西单抗治疗克罗恩病的疗效。方法收集第二军医大学长海医院2007年12月至2009年2月符合诊断标准的克罗恩病患者18例,使用英夫利西单抗进行治疗(5mg/kg静滴0、2、6周,以后每8周1次,维持46周),2周后观察疗效。结果使用英夫利西单抗治疗2周后,患者腹痛、腹泻等症状明显缓解,全身营养状况改善迅速,并发症如瘘管等均愈合良好,未出现明显不良反应,其中CDAI评分从321.5±34.5降为98.0±25.1(P<0.05);ESR(mm/h)从43.6±18.6(25～76)下降为6.8±3.1(P<0.05)。结论英夫利西单抗治疗克罗恩病具有确切的近期疗效且有很好的安全性,但远期疗效尚有待观察。
Objective To investigate the efficacy of Infliximab in the treatment of Crohn’s disease. Methods 18 patients with Crohn’s disease who met the diagnostic criteria from December 2007 to February 2009 in Changhai Hospital, Second Military Medical University were enrolled and treated with Infliximab (0, 2, 6 weeks after 5 mg / kg intravenous infusion Once every 8 weeks, maintaining 46 weeks), 2 weeks after the observation effect. Results After 2 weeks of treatment with infliximab, the symptoms such as abdominal pain and diarrhea were relieved and the general nutritional status improved rapidly. Complications such as fistulas healed well and no obvious adverse reactions occurred. The CDAI score decreased from 321.5 ± 34.5 to 98.0 ± 25.1 (P <0.05); ESR (mm / h) decreased from 43.6 ± 18.6 (25-76) to 6.8 ± 3.1 (P <0.05). Conclusion Infliximab treatment of Crohn’s disease with the exact effect of the recent and good safety, but the long-term efficacy remains to be seen.